These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

211 related items for PubMed ID: 34059001

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Indoleamine 2,3-Dioxygenase 1 (IDO1) Promotes Cardiac Hypertrophy via a PI3K-AKT-mTOR-Dependent Mechanism.
    Liu Y, Li S, Gao Z, Li S, Tan Q, Li Y, Wang D, Wang Q.
    Cardiovasc Toxicol; 2021 Aug; 21(8):655-668. PubMed ID: 34021461
    [Abstract] [Full Text] [Related]

  • 3. GPR39 promotes cardiac hypertrophy by regulating the AMPK-mTOR pathway and protein synthesis.
    Liao H, Gao W, Ma J, Xue H, Wang Y, Huang D, Yan F, Ye Y.
    Cell Biol Int; 2021 Jun; 45(6):1211-1219. PubMed ID: 33554444
    [Abstract] [Full Text] [Related]

  • 4. HTR2A promotes the development of cardiac hypertrophy by activating PI3K-PDK1-AKT-mTOR signaling.
    Gao W, Guo N, Zhao S, Chen Z, Zhang W, Yan F, Liao H, Chi K.
    Cell Stress Chaperones; 2020 Nov; 25(6):899-908. PubMed ID: 32519137
    [Abstract] [Full Text] [Related]

  • 5. Carboxypeptidase A4 promotes cardiomyocyte hypertrophy through activating PI3K-AKT-mTOR signaling.
    Gao W, Guo N, Zhao S, Chen Z, Zhang W, Yan F, Liao H, Chi K.
    Biosci Rep; 2020 May 29; 40(5):. PubMed ID: 32347291
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. PHD Finger Protein 19 Promotes Cardiac Hypertrophy via Epigenetically Regulating SIRT2.
    Gu W, Cheng Y, Wang S, Sun T, Li Z.
    Cardiovasc Toxicol; 2021 Jun 29; 21(6):451-461. PubMed ID: 33611744
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The histone demethylase PHF8 represses cardiac hypertrophy upon pressure overload.
    Liu X, Wang X, Bi Y, Bu P, Zhang M.
    Exp Cell Res; 2015 Jul 01; 335(1):123-34. PubMed ID: 25921086
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Irisin alleviates pressure overload-induced cardiac hypertrophy by inducing protective autophagy via mTOR-independent activation of the AMPK-ULK1 pathway.
    Li RL, Wu SS, Wu Y, Wang XX, Chen HY, Xin JJ, Li H, Lan J, Xue KY, Li X, Zhuo CL, Cai YY, He JH, Zhang HY, Tang CS, Wang W, Jiang W.
    J Mol Cell Cardiol; 2018 Aug 01; 121():242-255. PubMed ID: 30053525
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. MicroRNA-17-5p Promotes Cardiac Hypertrophy by Targeting Mfn2 to Inhibit Autophagy.
    Xu X, Su YL, Shi JY, Lu Q, Chen C.
    Cardiovasc Toxicol; 2021 Sep 01; 21(9):759-771. PubMed ID: 34120306
    [Abstract] [Full Text] [Related]

  • 14. PKD deletion promotes autophagy and inhibits hypertrophy in cardiomyocyte.
    Zhao D, Gao Y, Wang W, Pei H, Xu C, Zhao Z.
    Exp Cell Res; 2020 Jan 15; 386(2):111742. PubMed ID: 31759056
    [Abstract] [Full Text] [Related]

  • 15. Focal adhesion kinase governs cardiac concentric hypertrophic growth by activating the AKT and mTOR pathways.
    Clemente CF, Xavier-Neto J, Dalla Costa AP, Consonni SR, Antunes JE, Rocco SA, Pereira MB, Judice CC, Strauss B, Joazeiro PP, Matos-Souza JR, Franchini KG.
    J Mol Cell Cardiol; 2012 Feb 15; 52(2):493-501. PubMed ID: 22056317
    [Abstract] [Full Text] [Related]

  • 16. Rapamycin prevents thyroid hormone-induced cardiac hypertrophy.
    Kuzman JA, O'Connell TD, Gerdes AM.
    Endocrinology; 2007 Jul 15; 148(7):3477-84. PubMed ID: 17395699
    [Abstract] [Full Text] [Related]

  • 17. Resistin promotes cardiac hypertrophy via the AMP-activated protein kinase/mammalian target of rapamycin (AMPK/mTOR) and c-Jun N-terminal kinase/insulin receptor substrate 1 (JNK/IRS1) pathways.
    Kang S, Chemaly ER, Hajjar RJ, Lebeche D.
    J Biol Chem; 2011 May 27; 286(21):18465-73. PubMed ID: 21478152
    [Abstract] [Full Text] [Related]

  • 18. The PTPN11 loss-of-function mutation Q510E-Shp2 causes hypertrophic cardiomyopathy by dysregulating mTOR signaling.
    Schramm C, Fine DM, Edwards MA, Reeb AN, Krenz M.
    Am J Physiol Heart Circ Physiol; 2012 Jan 01; 302(1):H231-43. PubMed ID: 22058153
    [Abstract] [Full Text] [Related]

  • 19. GQ262 Attenuates Pathological Cardiac Remodeling by Downregulating the Akt/mTOR Signaling Pathway.
    Ma H, Ge Y, Di C, Wang X, Qin B, Wang A, Hu W, Lai Z, Xiong X, Qi R.
    Int J Mol Sci; 2024 Sep 25; 25(19):. PubMed ID: 39408627
    [Abstract] [Full Text] [Related]

  • 20. Activation or inactivation of cardiac Akt/mTOR signaling diverges physiological from pathological hypertrophy.
    Kemi OJ, Ceci M, Wisloff U, Grimaldi S, Gallo P, Smith GL, Condorelli G, Ellingsen O.
    J Cell Physiol; 2008 Feb 25; 214(2):316-21. PubMed ID: 17941081
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.